MeSH D009190 - myelodysplastic syndromes
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Azacitidine | Azacitidine Accord |  | 2020-02-13 |  |  |
| Decitabine | Decitabine |  | 2017-02-27 |  |  | |
| Lenalidomide | Lenalidomide Accord |  | 2018-09-20 |  |  | |
| Apotex | Lenalidomide | Lenalidomide |  | 2022-08-30 |  |  |
| Arrow International | Lenalidomide | Lenalidomide |  | 2021-05-21 |  |  |
| betapharm Arzneimittel | Azacitidine | Azacitidine betapharm |  | 2020-03-24 |  |  |
| Bristol Myers Squibb | Luspatercept | Reblozyl |  | 2020-06-25 | $1,156 M | Q2/23-Q1/24 |
| Lenalidomide | Revlimid | 2023-04-11 | 2005-12-27 | $6,016 M | Q2/23-Q1/24 | |
| Azacitidine | Vidaza |  | 2008-12-17 | $200 M | Q4/20-Q3/21 | |
| Celgene | Azacitidine | Azacitidine Celgene |  | 2019-08-02 |  |  |
| Cipla | Decitabine | Decitabine |  | 2017-11-16 |  |  |
| Lenalidomide | Lenalidomide |  | 2022-09-06 |  |  | |
| Dr Reddys Laboratories | Decitabine | Decitabine |  | 2013-07-11 |  |  |
| Lenalidomide | Lenalidomide |  | 2021-10-14 |  |  | |
| Eugia Pharma Specialties | Decitabine | Decitabine |  | 2021-09-20 |  |  |
| Lenalidomide | Lenalidomide |  | 2023-03-06 |  |  | |
| Gland Pharma | Decitabine | Decitabine |  | 2020-11-23 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
75%187/248
Phase 2
35%90/255
Phase 3
21%26/122
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use